智通财经APP获悉，艾迪康控股(09860)盘中涨超13%，截至发稿，涨9.24%，报8.39港元，成交额1416.29万港元。
湘财证券指出，近期AI+医疗备受市场关注。随着AI成熟度越来越高，其未来的应用场景和领域中也会出现更多的可能性，甚至可能会对一些行业造成颠覆性影响。该行提出，建议重点关注AI应用于临床诊断的相关ICL公司等。华创证券此前指出，国内ICL市场渗透率相较于国外仍有较大差距，在分级诊疗推进、医保控费压力加大、DRG/DIP付费方式改革、基层医疗建设的推动下，国内ICL行业有望进入快速发展期。
据悉，今年1月，首都医科大学临床检验中心与艾迪康达成战略合作，双方将共同探讨精准医学检验和病理诊断发展需求及医产学研合作模式，以推动创新诊断技术成果转化与临床应用，提高医疗服务质量。此外，根据艾迪康2024年12月16日公告显示，公司董事会将利用购回授权在公开市场购回不多于3628.72万股股份，占于本公告日期已发行股份总数的约5%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.